

Learner Notification

City of Hope

2026 COH - City of Hope Self Directed Intensive Course in Genomic Cancer Risk Assessment 2026-2027 Course

June 10, 2026 - June 10, 2027

Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. If you need MOC credit, you also need to pass a posttest with a score of at least 80%. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and City of Hope. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this blended activity for a maximum of 66.50 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 66.50 ANCC contact hours.

American Board of Internal Medicine (ABIM) MOC



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 66.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Physician Assistants



The National Commission on Certification of Physician Assistants (NCCPA) states that *AMA PRA Category 1 Credits™* are acceptable for continuing medical education requirements for recertification for PAs.

Amedco LLC designates this blended activity for a maximum of 66.50 *AMA PRA Category 1 Credits™*. PAs should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After Attending This Program You Should Be Able To

1. Integrate cancer genetics and oncology knowledge into clinical practice.
2. Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process.
3. Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions.
4. Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration.
5. Examine the value of hereditary cancer registries, cancer epidemiology and cancer prevention studies for patients and clinicians.
6. Realize greater professional self-efficacy related to genetic cancer risk assessment skills.
7. Incorporate Web-based resources into ongoing practice-based education, professional development, and research support.
8. Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Jill Bates	NA
Kathleen Blazer	Astra Zeneca:Research Grant Overall Principal Investigator
Kelly Bolton	Servier:Research Grant Overall Principal Investigator Servier:Scientific/Medical Advisory Board Member
ALEXANDRA CAPASSO	NA
Jane Churpek	UpToDate, Inc:Other
Julie Culver	NA
Madeline Currey	NA
Kathryn Dang	NA
Sandra Dreike	NA
Hunaydah Elfarawi	NA
Tobias Else	MERCK:Scientific/Medical Advisory Board Member
Melissa Frey	WndrHLTH, Atria:Consultant
Veda Giri	NA
Heather Hampel	Ambry Genetics:Scientific/Medical Advisory Board Member
Karen Hurley	NA
Gregory Idos	Adela:Research Grant Overall Principal Investigator
Joanne Jeter	NA
	PanTher Therapeutics, ROME Therapeutics, TellBio, Inc.:Private Stock Shareholder

Junne Kamihara	65 Therapeutics, ImproveBio, Inc., Leica Biosystems:Scientific/Medical Advisory Board Member abrdn, Astellas:Consultant Sanofi, Astellas, Incyte, ACD-Biotechne:Research Grant Overall Principal Investigator
Sonia Kupfer	NA
Allison Kurian	Ambry Genetics, Myriad Genetics, Labcorp, CARIS, Tempus, Foundation, Color, Gilead, Merck:Other
Amanda Laterza Ozarowski	GeneDx:Public Stock Shareholder
Phyllis Leung	NA
John Luna	NA
Lisa Madlensky	VieCure, DGI Inc:Scientific/Medical Advisory Board Member
Rachelle Manookian	NA
Kevin McDonnell	NA
Bitu Nehoray	NA
Gloria Nunez	NA
Wai Park	NA
Michelle Primiano	NA
Colin Pritchard	Arboretum Biosciences:Consultant
Padma Rajagopal	NA
Christina Rybak	Natera:Public Stock Shareholder
Ravi Sharaf	NA
Susan Shehayeb	NA
Brian Shuch	Telix, Merck, Vercyte:Consultant Histosonics:Speakers Bureau
Elise Sobotka	NA
Ilana Solomon	NA
Dev Tanna	NA
Michelle Weaver Knowles	Merck :Speakers Bureau
Kaila Wilson	NA
Elyssa Zukin	NA
Gloria Nunez	NA
Tracy Peterson	NA